Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) COO Sells 2,176 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,176 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total transaction of $41,344.00. Following the completion of the sale, the chief operating officer owned 62,371 shares of the company’s stock, valued at $1,185,049. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $43,500.00.

Monte Rosa Therapeutics Stock Down 0.5%

NASDAQ GLUE traded down $0.09 during trading hours on Thursday, hitting $18.32. 2,507,725 shares of the stock were exchanged, compared to its average volume of 1,308,502. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -12.38 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77. The stock has a 50-day moving average of $18.60 and a 200 day moving average of $18.47.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. On average, equities research analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC acquired a new stake in Monte Rosa Therapeutics in the 4th quarter valued at about $30,000. Russell Investments Group Ltd. purchased a new position in Monte Rosa Therapeutics during the 3rd quarter valued at about $32,000. Lazard Asset Management LLC raised its position in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares in the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GLUE. Wells Fargo & Company decreased their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Guggenheim decreased their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. upped their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.